Posted on November 8, 2018 by Sitemaster
We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation, failure, heart, side effect | 2 Comments »
Posted on September 3, 2017 by Sitemaster
Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, arrhythmia, cardiovascular, deprivation, failure, heart, risk | 9 Comments »
Posted on June 5, 2015 by Sitemaster
Zumsteg et al. searched the database at Memorial Sloan-Kettering Cancer Center (MSKCC) to determine the risk factors associated with cancer progression after primary radiation treatment, and the timing of progression. They report their results in European Urology, … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: failure, first line, outcome, radiation, surgery | 1 Comment »
Posted on January 26, 2015 by Sitemaster
The most widely used definition of biochemical failure after primary radiation therapy is the so-called “Phoenix” definition. It’s called that because it was adopted by consensus at a meeting of the American Society for Radiation Oncology (ASTRO) in Phoenix, AZ, in 2005. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, failure, primary, radiation therapy | 3 Comments »
Posted on February 1, 2013 by Sitemaster
For the patient with metastatic, castration-resistant prostate cancer (CRPC) there is an interesting new article (reprinted from the journal Expert Review of Anticancer Therapy) on the Medscape web site. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, chemotherapy, docetaxel, failure, metastatic | 5 Comments »
Posted on January 22, 2011 by Sitemaster
High-intensity focused ultrasound (HIFU) is approved in Canada for the treatment of localized prostate cancer. Since its approval, this form of treatment has become popular among patients seeking a potentially curative form of treatment with low risk for complications and side effects. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: failure, HIFU, high-intensity focuse ultrasound, outcome, salvage, surgery | Leave a comment »
Posted on October 19, 2010 by Sitemaster
As one of our regular commentators constantly points out, active surveillance (AS) is not a treatment for prostate cancer. It is a means by which to manage risk for prostate cancer progression in men with low- and very low-risk disease or higher-risk disease but a limited life expectancy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, failure, outcome, risk, success | 2 Comments »
Posted on April 13, 2010 by Sitemaster
One of the proposed uses for high-intensity focused ultrasound (HIFU) has been as a treatment option for men with a rising PSA after first-line treatment with external beam radiation therapy (EBRT). … READ MORE …
Filed under: Management, Treatment | Tagged: failure, HIFU, high-intensity focused ultrasound, outcome, radiation, salvage | Leave a comment »